EUVIMEDObjevte EUVIMED
Open access · CC BY-NC-ND 4.0

Analysis of iron status after initiation of elexacaftor/tezacaftor/ivacaftor in people with cystic fibrosis

Amber James, Galvin Li, Rhonda List, Kevin Lonabaugh iD, Aaron D Smith, Andrew Barros, Lindsay Somerville iD, Dana Albon

Pediatric Pulmonology · 2024

DOI: 10.1002/ppul.26805 ↗

At a glance

Journal article in Pediatric Pulmonology, 2024. Written by Amber James and 7 co-authors. Institution: Department of Medicine, University of Virginia School of Medicine, Charlottesville, Virginia, USA. Major MEDLINE topics: Iron, Cystic Fibrosis, Indoles, Pyrazoles. Cited 10 times so far (Crossref); 28 references. The full text is freely available (open access, CC BY-NC-ND 4.0). Funded by: CFF.

AbstraktSubjectsBibliografické údajeCiteRelated studies

Abstract (original language)

Background

Iron deficiency is highly prevalent in people with cystic fibrosis (PwCF). While elexacaftor/tezacaftor/ivacaftor (ETI) has shown remarkable improvements in respiratory symptoms in PwCF, the effect of ETI on iron status remains unknown. This study aims to identify the effect of ETI on iron status in PwCF.

Methods

A single‐center retrospective cohort study of 127 adult PwCF was conducted to assess the impact of ETI on iron, ferritin, transferrin levels, and percent saturation of transferrin (PSAT). Data were collected from the electronic medical record from January 2017 to September 2022, encompassing 2 years before and after ETI initiation. The primary outcome was serum iron parameters: iron, ferritin, transferrin, and PSAT levels following ETI treatment. Secondary outcomes analyzed iron supplementation. Univariate and multivariate mixed‐effects models were used for the analysis of ETI.

Results

After adjusting for covariates, following ETI initiation, the mean iron level increased by 20.24 μg/dL ( p < .001), ferritin levels were 31.4% ( p < .001) higher, PSAT showed a 5.09 percentage point increase ( p < .001), and transferrin levels increased by 2.71 mg/dL ( p = .439). Patients with and without iron supplementation experienced a significant increase in iron after ETI ( p < .001).

Conclusions

ETI is associated with a significant increase in iron, ferritin, and PSAT levels. Patients with and without iron supplementation demonstrated a significant increase in iron. This study shows the benefits of ETI on iron status in PwCF. However, further translational studies are required to understand the impact of ETI on iron absorption and metabolism in PwCF.

Subjects

MeSH terms (MEDLINE)

IronCystic FibrosisIndolesPyrazolesPyridinesPyrrolidinesQuinolonesAdultHumansRetrospective StudiesFerritinsTransferrinsCystic Fibrosis Transmembrane Conductance RegulatorMutationAminophenolsBenzodioxoles

Author keywords

cystic fibrosiselexacaftor/tezacaftor/ivacaftoriron status

Substances

IronelexacaftorivacaftortezacaftorFerritinsTransferrinsCystic Fibrosis Transmembrane Conductance RegulatorAminophenolsBenzodioxolesIndoles

Authors and institutions

  • Department of Medicine, University of Virginia School of Medicine, Charlottesville, Virginia, USA.
  • Department of Statistics, University of Virginia, Charlottesville, Virginia, USA.
  • Department of Medicine, Division of Pulmonology and Critical Care Medicine, University of Virginia, Charlottesville, Virginia, USA.

ORCID profiles: Kevin Lonabaugh, Lindsay Somerville

Funding

  • CFF

Cite

APA

James, A., Li, G., List, R., Lonabaugh, K., Smith, A. D., Barros, A., Somerville, L., & Albon, D. (2024). Analysis of iron status after initiation of elexacaftor/tezacaftor/ivacaftor in people with cystic fibrosis. Pediatric Pulmonology. https://doi.org/10.1002/ppul.26805

Vancouver

James A, Li G, List R, Lonabaugh K, Smith AD, Barros A, et al. Analysis of iron status after initiation of elexacaftor/tezacaftor/ivacaftor in people with cystic fibrosis. Pediatric Pulmonology. 2024. doi:10.1002/ppul.26805

BibTeX
@article{James2024,
  author = {James, Amber and Li, Galvin and List, Rhonda and Lonabaugh, Kevin and Smith, Aaron D and Barros, Andrew and Somerville, Lindsay and Albon, Dana},
  title = {Analysis of iron status after initiation of elexacaftor/tezacaftor/ivacaftor in people with cystic fibrosis},
  journal = {Pediatric Pulmonology},
  year = {2024},
  doi = {10.1002/ppul.26805}
}
Start for free →